1. Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. Issue 10 (25th May 2022) Authors: Sharma, Shringi; Pepin, Xavier; Cheung, Jean; Zheng, Lianqing; Wei, Hua; Townsley, Danielle; Han, David; Majewski, Michal; Ware, Joseph A.; Mann, James; Munugalavadla, Veerendra; Sheridan, Louise; Patel, Priti; Gupta, Ashok; Tomkinson, Helen Other Names: Gacia‐Bournissen Facundo guestEditor.; Rieder Michael guestEditor. Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 10(2022) Page Start: 4573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors. Issue 11 (27th August 2022) Authors: Sharma, Shringi; Pepin, Xavier; Burri, Harini; Zheng, Lianqing; Kuptsova‐Clarkson, Nataliya; de Jong, Anouk; Yu, Ting; MacArthur, Holly L.; Majewski, Michal; Byrd, John C.; Furman, Richard R.; Ware, Joseph A.; Mann, James; Ramies, David; Munugalavadla, Veerendra; Sheridan, Louise; Tomkinson, Helen Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 11(2022) Page Start: 1294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Concentration‐QT modelling in early clinical oncology settings: Simulation evaluation of performance. Issue 3 (9th September 2021) Authors: Cantet, Gael; Berges, Alienor; O'Sullivan, Rhianna; Cohen‐Rabbie, Sarit; Dota, Corina; Dubois, Vincent; Benoist, Guillemette E.; Tomkinson, Helen; Rekić, Dinko; Parkinson, Joanna; Schalkwijk, Stein Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 3(2022) Page Start: 1010 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. Issue 5 (8th February 2017) Authors: Tang, Weifeng; Tomkinson, Helen; Masson, Eric Journal: Clinical pharmacology in drug development Issue: Volume 6:Issue 5(2017) Page Start: 517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and Safety Exposure‐Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients. Issue 6 (22nd February 2019) Authors: Zhou, Diansong; Li, Jianguo; Learoyd, Maria; Bui, Khanh; Berges, Alienor; Milenkova, Tsveta; Al‐Huniti, Nidal; Tomkinson, Helen; Xu, Hongmei Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 6(2019) Page Start: 1492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies. Issue 5 (17th October 2021) Authors: Edlund, Helena; Buil‐Bruna, Núria; Vishwanathan, Karthick; Wei, Helen; Raman, Rakesh; de Kock, Miné; He, Zhongqing; Liu, Huan; Baek, Marshall; Ware, Joseph; Patel, Priti; Tomkinson, Helen; Sharma, Shringi Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 5(2022) Page Start: 2284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology. (10th December 2018) Authors: Farha, Mark; Masson, Eric; Tomkinson, Helen; Mugundu, Ganesh Journal: Journal of clinical pharmacology Issue: Volume 59:Number 4(2019) Page Start: 463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Harnessing Meta‐analysis to Refine an Oncology Patient Population for Physiology‐Based Pharmacokinetic Modeling of Drugs. Issue 2 (20th November 2017) Authors: Schwenger, Emily; Reddy, Venkatesh Pilla; Moorthy, Ganesh; Sharma, Pradeep; Tomkinson, Helen; Masson, Eric; Vishwanathan, Karthick Journal: Clinical pharmacology & therapeutics Issue: Volume 103:Issue 2(2018) Page Start: 271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach. Issue 2 (21st August 2021) Authors: Edlund, Helena; Bellanti, Francesco; Liu, Huan; Vishwanathan, Karthick; Tomkinson, Helen; Ware, Joseph; Sharma, Shringi; Buil‐Bruna, Núria Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 2(2022) Page Start: 846 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens. (22nd July 2021) Authors: Cohen‐Rabbie, Sarit; Zhou, Li; Vishwanathan, Karthick; Wild, Martin; Xu, Sherrie; Freshwater, Tomoko; Jain, Lokesh; Schalkwijk, Stein; Tomkinson, Helen; Zhou, Diansong Journal: Journal of clinical pharmacology Issue: Volume 61:Number 11(2021) Page Start: 1493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗